BridgeBio Pharma (BBIO) PT Raised to $96 at BofA Securities
Tweet Send to a Friend
BofA Securities analyst Jason Zemansky raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $96.00 (from $95.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
